Cited by 752Bone health and osteoporosis researchMenopause: Health Impacts and TreatmentsBone health and treatments

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

Cummings, Steven R., Karpf, David B., Harris, Fran, Genant, Harry K., Ensrud, Kristine, LaCroix, Andrea Z., Black, Dennis M.·2002·The American Journal of Medicine

DOI 10.1016/s0002-9343(01)01124-x

Open this paper in CoChat — free account

Abstract

Purpose To estimate how much the improvement in bone mass accounts for the reduction in risk of vertebral fracture that has been observed in randomized trials of antiresorptive treatments for osteoporosis.Methods After a systematic search, we conducted a meta-analysis of 12 trials to describe the relation between improvement in spine bone mineral density and reduction in risk of vertebral fracture in postmenopausal women. We also used logistic models to estimate the proportion of the reduction in risk of vertebral fracture observed with alendronate in the Fracture Intervention Trial that was due to improvement in bone mineral density.Results Across the 12 trials, a 1% improvement in spine bone mineral density was associated with a 0.03 decrease (95% confidence interval [CI]: 0.02 to 0.05) in the relative risk (RR) of vertebral fracture. The reductions in risk were greater than predicted from improvement in bone mineral density; for example, the model estimated that treatments predicted to reduce fracture risk by 20% (RR = 0.80), based on improvement in bone mineral density, actually reduce the risk of fracture by about 45% (RR = 0.55). In the Fracture Intervention Trial, improvement in spine bone mineral density explained 16% (95% CI: 11% to 27%) of the reduction in the risk of vertebral fracture with alendronate.Conclusion Improvement in spine bone mineral density during treatment with antiresorptive drugs accounts for a predictable but small part of the observed reduction in the risk of vertebral fracture.

Integrity signals

Registry

Crossref · 10.1016/s0002-9343(01)01124-x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citation
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>
Ettinger, B. (1999) · JAMA · doi:10.1001/jama.282.7.637 · Cited by 3,366
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475
Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citation
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276
Self-citation
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Self-citation
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M. C., Marcelli, C., Grandjean, H., Müller, C., Cormier, C., Bréart, G., Meunier, P. J., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 984
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947
Self-citation

Show all 35 references

Research works printed but not linked: 4

Cummings, 1996, Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs, J Bone Miner Res, 11, S102
Genant, 1998, Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis, Bone, 23, S175
Black, 1993, Prediction of new vertebral deformities, J Bone Miner Res, 8, S135
Cann, 1999, PTH effects in the femur, J Bone Miner Res, 14, S137

Sorted by citations

Items 201–300 of 751

Bone quality and osteoporosis therapy
Martin, R. M., & Corrêa, P. H. S. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200015 · Cited by 63
The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults
Bhadada, S. K., Chadha, M. D., Sriram, U., Pal, R., Paul, T. V., Khadgawat, R., Joshi, A. S., Bansal, B., Kapoor, N., Aggarwal, A., et al. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00954-1 · Cited by 65
Automated registration of hip and spine for longitudinal QCT studies: Integration with 3D densitometric and structural analysis
Li, W., Sode, M., Saeed, I., & Lang, T. (2005) · Bone · doi:10.1016/j.bone.2005.08.014 · Cited by 59
Bisphosphonates: new indications and methods of administration
Reid, I. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00014 · Cited by 60
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study
Paggiosi, M., Peel, N. F. A., McCloskey, E. V., Walsh, J., & Eastell, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2817-z · Cited by 59
Choosing Wisely: The Canadian Rheumatology Association’s List of 5 Items Physicians and Patients Should Question
Chow, S. L., Thorne, J. C., Bell, M. J., Ferrari, R., Bagheri, Z., Boyd, T., Colwill, A. M., Jung, M., Frackowiak, D., Hazlewood, G. S., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141140 · Cited by 59
Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis
Eviö, S., Tiitinen, A. E., Laitinen, K., Ylikorkala, O., & Välimäki, M. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030198 · Cited by 59
Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss
Zaidi, M., Turner, C. H., CANALIS, E. M., Pacifici, R., Sun, L., Iqbal, J. Z., Guo, X. E., Silverman, S. S., Epstein, S., & Rosen, C. J. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0021-4 · Cited by 55
Early Changes in Biochemical Markers of Bone Turnover Predict Bone Mineral Density Response to Antiresorptive Therapy in Korean Postmenopausal Women with Osteoporosis
Kim, S. W., Park, D. J., Park, K. S., Kim, S. Y., Cho, B. Y., Lee, H. K., & Shin, C. S. (2005) · Endocrine Journal · doi:10.1507/endocrj.52.667 · Cited by 58
A human mission to Mars: Predicting the bone mineral density loss of astronauts
Axpe, E., Chan, D., Abegaz, M. F., Schreurs, A.-S., Alwood, J. S., Globus, R. K., & Appel, E. A. (2020) · PLOS ONE · doi:10.1371/journal.pone.0226434 · Cited by 57
“Bone density is an important parameter that contributes to bone strength, but it would be both interesting and important to include other parameters that contribute to so-called “bone quality” in future studies (such as microarchitecture and material properties) to gain a more accurate estimate of fracture probability…”
Background
Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment
Koltsov, J. C. B., Brooks, D. J., MacLeay, J. M., Baker, S. P., Boskey, A. L., & van der Meulen, M. C. H. (2012) · Bone · doi:10.1016/j.bone.2012.10.018 · Cited by 60
The influence of boundary conditions and loading mode on high-resolution finite element-computed trabecular tissue properties
Bevill, G. R., Eswaran, S. K., Farahmand, F., & Keaveny, T. M. (2008) · Bone · doi:10.1016/j.bone.2008.11.015 · Cited by 57
Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment
Shiraki, M., Kuroda, T., Shiraki, Y., Tanaka, S., Higuchi, T., & Saito, M. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0191-2 · Cited by 55
Targeting Bone Remodeling for the Treatment of Osteoporosis: Summary of the Proceedings of an ASBMR Workshop
Bilezikian, J. P., Matsumoto, T., Bellido, T., Khosla, S., Martin, J. W., Recker, R. R., Heaney, R. P., Seeman, E., Papapoulos, S. E., & Goldring, S. R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090105 · Cited by 59
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis
Gallagher, J. C., Rosen, C. J., Chen, P., Misurski, D. A., & Marcus, R. (2006) · Bone · doi:10.1016/j.bone.2006.06.007 · Cited by 56
Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*
Luckey, M. M., Kagan, R., Greenspan, S. L., Bone, H. G., Kiel, R. D. P., Simon, J. A., Sackarowitz, J., Palmisano, J. J., Chen, E., Petruschke, R. A., et al. (2004) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000119981.77837.1f · Cited by 57
Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?
Li, Z., Chines, A. A., & Meredith, M. P. (2004) · PubMed · Cited by 55
Skeletal Heterogeneity and the Purposes of Bone Remodeling
PARFITT, A. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00036-4 · Cited by 54
Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products
Bonjour, J., Kohrt, W. M., Levasseur, R., Warren, M. P., Whiting, S. J., & KRAENZLIN, M. E. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000183 · Cited by 57
Hormones and Bone Health in Postmenopausal Women
Lindsay, R. (2004) · Endocrine · doi:10.1385/endo:24:3:223 · Cited by 54
Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes
Boonen, S., Haentjens, P., Vandenput, L., & Vanderschueren, D. (2003) · Journal of Internal Medicine · doi:10.1046/j.0954-6820.2003.01258.x · Cited by 54
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x100276 · Cited by 53
Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
Sugimoto, T., Nakamura, T., Nakamura, Y., Isogai, Y., & Shiraki, M. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2516-1 · Cited by 53
Systems genetics in diversity outbred mice inform BMD GWAS and identify determinants of bone strength
Al-Barghouthi, B. M., Mesner, L. D., Calabrese, G. M., Brooks, D. J., Tommasini, S. M., Bouxsein, M., Horowitz, M. C., Rosen, C. J., Nguyen, K. K., Haddox, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23649-0 · Cited by 56
Bisphosphonate Use in Acute and Chronic Spinal Cord Injury: A Systematic Review
Bryson, J. E., & Gourlay, M. L. (2009) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2009.11760776 · Cited by 53
Reduced Tissue-Level Stiffness and Mineralization in Osteoporotic Cancellous Bone
Kim, G., Cole, J. H., Boskey, A. L., Baker, S. P., & van der Meulen, M. C. H. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9873-4 · Cited by 52
Bone Mineral Density, Serum Albumin and Serum Magnesium
Saito, N., Tabata, N., Saito, S., Andou, Y., Onaga, Y., Iwamitsu, A., Sakamoto, M., Hori, T., Sayama, H., & Kawakita, T. (2004) · Journal of the American College of Nutrition · doi:10.1080/07315724.2004.10719412 · Cited by 52
Anti-resorptives in the management of osteoporosis
Miller, P. D. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.004 · Cited by 51
Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long‐term calorie restriction with adequate nutrition
Villareal, D. T., Kotyk, J. J., Armamento‐Villareal, R. C., Kenguva, V., Seaman, P., Shahar, A., Wald, M. J., Kleerekoper, M., & Fontana, L. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00643.x · Cited by 51
Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures
Vokes, T., Giger, M. L., Chinander, M. R., Karrison, T. G., Favus, M. J., & Dixon, L. B. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0089-y · Cited by 51
Evaluation of Compressive Strength Index of the Femoral Neck in Caucasians and Chinese
Yu, N., Liu, Y.-J., Pei, Y., Zhang, L., Lei, S., Kothari, N. R., Li, D.-Y., Papasian, C. J., Hamilton, J. J., Cai, J., et al. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9406-8 · Cited by 51
Development and Validation of a Predictive Bone Fracture Risk Model for Astronauts
Nelson, E. S., Lewandowski, B., Licata, A., & Myers, J. G. (2009) · Annals of Biomedical Engineering · doi:10.1007/s10439-009-9779-x · Cited by 50
Long-term bisphosphonate usage and subtrochanteric insufficiency fractures
Yoon, R. S., Hwang, J., & Beebe, K. S. (2011) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.93b10.26924 · Cited by 49
Precision and accuracy of measuring changes in bone mineral density by dual-energy X-ray absorptiometry
Tothill, P., & Hannan, W. J. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0382-4 · Cited by 49
Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate
Bruyère, O., Roux, C., Badurski, J. E., Isaia, G., de Vernejoul, M. C., Cannata-Andía, J. B., Ortolani, S., Slosman, D. O., Detilleux, J., & Reginster, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x242818 · Cited by 49
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M., & Haentjens, P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02010.x · Cited by 50
Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy
Greenspan, S. L., Wagner, J. M., Nelson, J. B., Perera, S., Britton, C. A., & Resnick, N. M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1771 · Cited by 48
Tomografia computadorizada quantitativa periférica de alta resolução para avaliação de parâmetros morfológicos e funcionais ósseos
Fuller, H., Fuller, R., & Pereira, R. M. R. (2014) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2014.07.010 · Cited by 48
NOFSA Guideline for the Diagnosis and Management of Osteoporosis
Hough, S. F., Ascott-Evans, B. H., Brown, S. L., Cassim, B., de Villiers, T. J., Lipschitz, S., Pettifor, J. M., & Sonnendecker, E. W. W. (2010) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2010.10872239 · Cited by 48
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International
Reid, D. M., Hosking, D. J., Kendler, D. L., Brandi, M. L., Wark, J. D., Marques-Neto, J. F., Weryha, G., Verbruggen, N., Hustad, C. M., Mahlis, E. M., et al. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01704.x · Cited by 47
Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: A prospective randomized clinical trial
Mawatari, T., Miura, H., Hamai, S., Shuto, T., Nakashima, Y., Okazaki, K., Kinukawa, N., Sakai, S., Hoffmann, P. F., Iwamoto, Y., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23988 · Cited by 46
Perspectives on the non-invasive evaluation of femoral strength in the assessment of hip fracture risk
on behalf of the IOF Working Group on Hip Bone Strength as a Therapeutic Target, Bouxsein, M., Zysset, P. K., Glüer, C.-C., McClung, M. R., Biver, E., Pierroz, D. D., & Ferrari, S. (2020) · Osteoporosis International · doi:10.1007/s00198-019-05195-0 · Cited by 47
What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring?
Briot, K., & Roux, C. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.06.004 · Cited by 47
Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates
Olmos, J. M., Zarrabeitia, M. T., Hernández, J. L., Sañudo, C., González-Macı́as, J., & Riancho, J. A. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.88 · Cited by 46
Clinical application of biochemical markers of bone turnover
Seibel, M. J. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400006 · Cited by 46
Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment
Sebba, A. I. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.03.008 · Cited by 47
Fracture Threshold and Risk for Osteoporosis and Pathologic Fractures in Individuals with Spinal Cord Injury
Garland, D. E., Adkins, R. H., & Stewart, C. (2005) · Topics in Spinal Cord Injury Rehabilitation · doi:10.1310/g6td-hpgc-xm3q-7yjh · Cited by 46
Remodeling and skeletal fragility
Heaney, R. P. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1466-4 · Cited by 46
Bisphosphonates pharmacology and use in the treatment of osteoporosis
Diab, D. L., Watts, N. B., & Miller, P. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00074-5 · Cited by 46
Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2
Otomo, H., Sakai, A., Ikeda, S., Tanaka, S., Ito, M., Phipps, R. J., & Nakamura, T. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0502-6 · Cited by 43
Tomography-Based Quantification of Regional Differences in Cortical Bone Surface Remodeling and Mechano-Response
Birkhold, A., Razi, H., Duda, G. N., Checa, S., & Willie, B. M. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0217-4 · Cited by 43
Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment
Park, S. Y., Ahn, S. H., Yoo, J., Chung, Y., Jeon, Y. K., Yoon, B., Kim, H. Y., Lee, S. H., Lee, J., & Hong, S. (2019) · Journal of Bone Metabolism · doi:10.11005/jbm.2019.26.4.213 · Cited by 46
Advances in Therapy for Osteoporosis
Heaney, R. P. (2003) · Clinical Medicine & Research · doi:10.3121/cmr.1.2.93 · Cited by 43
Effects of Cyclic Versus Daily hPTH(1-34) Regimens on Bone Strength in Association With BMD, Biochemical Markers, and Bone Structure in Mice
Iida‐Klein, A., Hughes, C., Lu, S. S., Moreno, A., Shen, V., Dempster, D. W., Cosman, F., & Lindsay, R. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051017 · Cited by 45
Calcitonin
Silverman, S. L. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00060-9 · Cited by 43
A new quality of bone ultrasound research
Glüer, C.-C. (2008) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2008.828 · Cited by 42
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis
Vescini, F., Attanasio, R., Balestrieri, A., Bandeira, F. A. F., Bonadonna, S., Camozzi, V., Cassibba, S., Cesareo, R., Chiodini, I., Francucci, C. M., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0434-8 · Cited by 43
Quantitative two‐dimensional ultrashort echo time magnetization transfer (2D UTE‐MT) imaging of cortical bone
Ma, Y., Tadros, A. S., Du, J., & Chang, E. Y. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26846 · Cited by 42
Trabecular Bone Structure Analysis in the Osteoporotic Spine Using a Clinical In Vivo Setup for 64-Slice MDCT Imaging: Comparison to μCT Imaging and μFE Modeling
Issever, A. S., Link, T. M., Kentenich, M., Rogalla, P., Schwieger, K., Huber, M., Burghardt, A. J., Majumdar, S., & Diederichs, G. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090311 · Cited by 42
Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?
Blake, G. M., Compston, J. E., & Fogelman, I. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090601 · Cited by 38
A Comprehensive Approach to Fragility Fractures
Rebolledo, B. J., Unnanuntana, A., & Lane, J. M. (2011) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e3181f9b389 · Cited by 41
Femoral Neck Trabecular Microstructure in Ovariectomized Ewes Treated With Calcitonin: MRI Microscopic Evaluation
Jiang, Y., Zhao, J., Geusens, P., Liao, E.-Y., Adriaensens, P., Gelan, J., Azria, M., Boonen, S., Caulin, F., Lynch, J. A., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041008 · Cited by 41
Self-citation
Menatetrenone (Vitamin K2) and Bone Quality in the Treatment of Postmenopausal Osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2006) · Nutrition Reviews · doi:10.1111/j.1753-4887.2006.tb00184.x · Cited by 42
The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong.
Ip, T., Cheung, S.-K. W., Cheung, S.-K. W., Cheung, T.-C., Choi, T.-C., Chow, S.-L. E., Kan, S.-Y. A., Kung, W. C. A., Lee, K.-K., Leung, K. L. F., et al. (2013) · PubMed · Cited by 41
Prolonged Treatments With Antiresorptive Agents and PTH Have Different Effects on Bone Strength and the Degree of Mineralization in Old Estrogen-Deficient Osteoporotic Rats
Cheng, Z., Yao, W., Zimmermann, E. A., Busse, C., Ritchie, R. O., & Lane, N. E. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.81005 · Cited by 40
The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
Goessl, C. D., Katz, L., Dougall, W. C., Kostenuik, P. J., Zoog, H. B., Braun, A., Dansey, R., & Wagman, R. B. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06674.x · Cited by 40
Osteoporosis prevention and therapy: preserving and building strength through bone quality
Kleerekoper, M. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0187-x · Cited by 40
Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression
Rabenda, V., Bruyère, O., & Reginster, J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1469-x · Cited by 39
Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality
van der Meulen, M. C. H., & Boskey, A. L. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4013 · Cited by 39
What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?
Miller, P. D., & Derman, R. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1208-3 · Cited by 39
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass
Bonnick, S. L., Beck, T., Cosman, F., Hochberg, M. C., Wang, H., & de Papp, A. E. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0762-4 · Cited by 39
Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis
Roux, C., Garnero, P., Thomas, T., Sabatier, J., Orcel, P., & Audran, M. (2004) · Joint Bone Spine · doi:10.1016/j.jbspin.2004.07.003 · Cited by 39
Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces
Hofstetter, B., Gamsjaeger, S., Phipps, R. J., Recker, R. R., Ebetino, F. H., Klaus Klaushofer, A., & Paschalis, E. P. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1572 · Cited by 38
Bisphosphonates and atypical subtrochanteric fractures of the femur
Kharwadkar, N., Mayne, B., Lawrence, J. E. G., & Khanduja, V. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.63.bjr-2016-0125.r1 · Cited by 39
Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
Martin, T. J. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.01.002 · Cited by 38
Greater Fruit Intake was Associated With Better Bone Mineral Status Among Chinese Elderly Men and Women: Results of Hong Kong Mr. Os and Ms. Os Studies
Liu, Z., Leung, J. C. S., Wong, S. Y. S., Wong, C. K. M., Chan, R., & Woo, J. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.11.001 · Cited by 37
Osteoporosis: disease severity and consequent fracture management
Cooper, C. C. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1251-0 · Cited by 37
Fracture Risk Assessment
Cozadd, A. J., Schroder, L. K., & Switzer, J. A. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.01071 · Cited by 37
Skeletal Heterogeneity and the Purposes of Bone Remodeling: Implications for the Understanding of Osteoporosis
PARFITT, A. M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50007-0 · Cited by 37
Diagnosis and Management of Osteoporosis: A Comprehensive Review of Guidelines
Rentzeperi, E., Pegiou, S., Tsakiridis, I. G., Kalogiannidis, I. A., Kourtis, A., Mamopoulos, A. M., Athanasiadis, A. P., & Dagklis, T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001181 · Cited by 39
An agenda for UK clinical pharmacology: Monitoring drug therapy
Buclin, T., Gotta, V., Fuchs, A., Widmer, N., & Aronson, J. K. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04237.x · Cited by 37
Osteoporosis considerations in the frail elderly
Suh, T. T., & Lyles, K. W. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00018 · Cited by 36
Osteoporosis: Differences and Similarities in Male and Female Patients
Lane, J. M., Serota, A. C., & Raphael, B. S. (2006) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2006.09.002 · Cited by 36
Effects of ibandronate on bone quality: Preclinical studies
Bauss, F., & Dempster, D. W. (2006) · Bone · doi:10.1016/j.bone.2006.08.002 · Cited by 36
Dual-energy X-ray absorptiometry and fracture prediction in patients with spinal cord injuries and disorders
Abderhalden, L. A., Weaver, F. M., Bethel, M., Demirtaş, H., Burns, S. P., Svircev, J. N., Hoenig, H., Lyles, K. W., Miskevics, S. A., & Carbone, L. D. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3841-y · Cited by 36
Change in Trabecular Bone Score (TBS) With Antiresorptive Therapy Does Not Predict Fracture in Women: The Manitoba BMD Cohort
Leslie, W. D., Majumdar, S. R., Morin, S. N., Hans, D. B., & Lix, L. M. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3054 · Cited by 36
Examining the Relationship Between Bone Mineral Density and Fracture Risk Reduction During Pharmacologic Treatment of Osteoporosis
DiVittorio, G., Jackson, K. L., Chindalore, V. L., Welker, W., & Walker, J. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2006.26.1.104 · Cited by 37
A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke
Kang, J., Keller, J. J., & Lin, H. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1894-0 · Cited by 34
Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials
Lou, S., Lv, H., Li, Z., Zhang, L., & Tang, P. (2018) · BMJ Open · doi:10.1136/bmjopen-2016-015187 · Cited by 35
Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis
Sebba, A. I., Emkey, R. D., Kohles, J. D., & Sambrook, P. N. (2008) · Bone · doi:10.1016/j.bone.2008.10.052 · Cited by 35
Clinical Use of Teriparatide in the Real World: Initial Insights
Miller, P. D., Bilezikian, J. P., Deal, C. L., Harris, S. T., & Pacifici, R. (2004) · Endocrine Practice · doi:10.4158/ep.10.2.139 · Cited by 35
Concept of a Radiofrequency Device for Osteopenia/Osteoporosis Screening
Makarov, S. N., Noetscher, G. M., Arum, S., Rabiner, R., & Nazarian, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-60173-5 · Cited by 34
Multi-level patient-specific modelling of the proximal femur. A promising tool to quantify the effect of osteoporosis treatment
Lenaerts, L., & van Lenthe, H. (2009) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2008.0302 · Cited by 34
Longitudinal Analysis of Mesenchymal Progenitors and Bone Quality in the Stem Cell Antigen-1–Null Osteoporotic Mouse
Holmes, C. A., Khan, T., Owen, C., Ciliberti, N., Grynpas, M. D., & Stanford, W. L. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070604 · Cited by 34
Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis
Iwamoto, J., Satō, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2008) · Yonsei Medical Journal · doi:10.3349/ymj.2008.49.1.119 · Cited by 34
Retracted
Endogenous Estrogen Levels and the Effects of Ultra-Low-Dose Transdermal Estradiol Therapy on Bone Turnover and BMD in Postmenopausal Women
Huang, A. J., Ettinger, B. B., Vittinghoff, E., Ensrud, K. E., Johnson, K., & Cummings, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070707 · Cited by 34
Self-citation
Use of randomised trials to decide when to monitor response to new treatment
Bell, K., Irwig, L., Craig, J. C., & Macaskill, P. (2008) · BMJ · doi:10.1136/bmj.39476.623611.25 · Cited by 34
Impact of a community pharmacist‐directed clinic in improving screening and awareness of osteoporosis
Law, A. V., & Shapiro, K. (2005) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2005.00531.x · Cited by 34
Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone??Density and Turnover in Postmenopausal Women with Osteoporosis
Reid, D. M., Hosking, D. J., Kendler, D. L., Brandi, M. L., Wark, J. D., Weryha, G., Marques-Neto, J. O. F., Gaines, K. A., Verbruggen, N., & Melton, M. E. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626020-00002 · Cited by 35
The effect of osteoporosis treatments on fatigue properties of cortical bone tissue
Brock, G. R., Chen, J. T., Ingraffea, A. R., MacLeay, J., Pluhar, G. E., Boskey, A. L., & van der Meulen, M. C. H. (2015) · Bone Reports · doi:10.1016/j.bonr.2014.10.004 · Cited by 33

Authors: Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M.
Affiliations: University of California, San Francisco (US)
Geron (United States) (US)
University of Minnesota (US)
University of Washington (US)
Corresponding author: Cummings, Steven R.
ORCID: Cummings, Steven R.
Genant, Harry K.
Ensrud, Kristine
LaCroix, Andrea Z.
Black, Dennis M.
Venue: The American Journal of Medicine
Publisher: Elsevier BV
Published: 2002-03
Volume: 112
Issue: 4
Pages: 281-289
ISSN: 0002-9343 (ISSN-L)
DOI: 10.1016/s0002-9343(01)01124-x
OpenAlex: W2110828193
Cited by: 752
References: 35
Citations by year: 2026: 7 · 2025: 10 · 2024: 17 · 2023: 12 · 2022: 12 · 2021: 16 · 2020: 25 · 2019: 10 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 19 · 2014: 24 · 2013: 29 · 2012: 43
FWCI: 8.42
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The American Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: osteoporosis, vertebral fractures, bone mineral density, antiresorptive agents, alendronate, postmenopausal women, Fracture Intervention Trial, fracture risk reduction, bone mass
MeSH terms: Bone Resorption, Female, Fractures, Spontaneous, Humans, Regression Analysis, Risk Factors, Spine, Bone Density, Osteoporosis, Postmenopausal, Logistic Models, Spinal Fractures, Alendronate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks